(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 34.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Cue Biopharma's revenue in 2025 is $7,991,000.On average, 1 Wall Street analysts forecast CUE's revenue for 2025 to be $482,239,238, with the lowest CUE revenue forecast at $482,239,238, and the highest CUE revenue forecast at $482,239,238. On average, 1 Wall Street analysts forecast CUE's revenue for 2026 to be $753,498,810, with the lowest CUE revenue forecast at $753,498,810, and the highest CUE revenue forecast at $753,498,810.
In 2027, CUE is forecast to generate $1,544,672,561 in revenue, with the lowest revenue forecast at $1,544,672,561 and the highest revenue forecast at $1,544,672,561.